Liew, Adrian; Bavanandan, Sunita; Prasad, Narayan; Wong, Muh Geot; Chang, Jer Ming; Eiam‐Ong, Somchai; Hao, Chuan‐Ming; Lim, Chiao Yuen; Lim, Soo Kun; OH, Kook‐Hwan; Okada, Hirokazu; Susantitaphong, Paweena; Lydia, Aida; Tran, Huong Thi Bich; Villanueva, Russell; Yeo, See Cheng; Tang, Sydney C.W.
doi: 10.1111/nep.13804pmid: 33111435
Nakano, Kiyoshi; Kubota, Yasuo; Mori, Takayuki; Chiga, Motoko; Mori, Takayasu; Sonoda, Shyunya; Ueda, Daisuke; Asakura, Isao; Ikegaya, Takeshi; Kagawa, Jiro; Uchida, Shinichi; Kubota, Akira
doi: 10.1111/nep.13752
Stephen, Shiny; Park, Yeung‐Ae; Chrysostomou, Anastasia
doi: 10.1111/nep.13767pmid: 32776624
COVID‐19 remains a global pandemic with more than 10 million cases and half a million deaths worldwide. The disease manifestations in patients with chronic kidney disease and especially those on haemodialysis are still being understood, with only a few overseas case series, and small observational trials thus far. It appears that the disease is more severe in this patient cohort. Part of the pathophysiology of severe COVID‐19 is related to accompanying cytokine release syndrome (CRS). Tocilizumab, an interleukin‐6 inhibitor, has been trialled for treatment of CRS in COVID‐19, but not yet approved. We present a case of an Australian patient on long‐term haemodialysis with severe COVID‐19 who was successfully treated with Tocilizumab. The peak of her illness was on day 7, with a C‐reactive protein of 624 mg/L (reference < 5 mg/L), ferritin of 5293 ng/mL (reference 30‐500 ng/mL), and interleukin‐6 level 1959.7 pg/mL, consistent with CRS. She was severely hypoxic on a ventilator, with rising inotropic requirements. With the use of Tocilizumab, there was a significant and immediate response in her inflammatory markers, and she made a steady recovery. The patient was discharged home 6 weeks after presentation.
Leme, Juliana; Guedes, Murilo; Larkin, John; Han, Maggie; Barra, Ana Beatriz Lesqueves; Canziani, Maria Eugenia F.; Cuvello Neto, Américo Lourenço; Poli‐de‐Figueiredo, Carlos Eduardo; Moraes, Thyago Proenca; Pecoits‐Filho, Roberto; ,
doi:
Showing 1 to 10 of 12 Articles
Pseudohypoaldosteronism type II (PHA II) is inherited in an autosomal dominant manner and is characterized by hypertension, hyperkalemia, and hyperchloremic metabolic acidosis. The enhancement of with‐no‐lysine kinase (WNK) functions is correlated to the pathogenesis of the condition. Cullin 3 (CUL3) forms an E3 ubiquitin ligase complex, and it can ubiquitinate WNK. Most CUL3 gene mutations are distributed in sites, such as intron 8 splice acceptor, intron 9 splice donor, and putative intron 8 splice branch sites, which are involved in the splicing of exon 9. These mutations result in the deletion of exon 9, which reduces the activity of ubiquitination against WNK and inhibits the degradation of WNK. In this report, we identified a novel CUL3 c.1312A>G mutation in familial cases. A mutation prediction software showed that the significance of these mutations was not clear. However, using the Human Splicing Finder 3.1 software, in silico analyses revealed that these mutations induced splicing alterations, which affected the sites of exon 9, altered the balance between predicted exonic splicing enhancers and silencers, and led to the deletions of exon 9. This study presented a novel pathogenic splicing variant to the CUL3 mutation and provided a reference for further research about the mechanisms of splicing. Moreover, it showed that not only amino acid substitution caused by nonsynonymous mutations but also splicing motif changes due to base substitutions have important roles in the pathogenesis of PHA II.